ARTICLE | Company News

GlaxoSmithKline, University of Texas MD Anderson Cancer Center deal

April 14, 2014 7:00 AM UTC

The center partnered with GlaxoSmithKline to develop immunotherapies for cancer through MD Anderson's Moon Shots Program. GSK declined to disclose details, and the center could not be reached. The center said this is the fourth and final major collaboration with a large company. In March, the cancer center partnered with the MedImmune LLC biologics unit of AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) under the program (see BioCentury, March 24). ...